12 years of historical data (2013–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Molecular Partners AG currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $188M | $162M | $137M | $218M | $595M | — | — | — | — | — | — |
| Enterprise Value | $108M | $100M | $73M | $135M | $529M | — | — | — | — | — | — |
| P/E Ratio → | -2.43 | — | — | 1.85 | — | — | — | — | — | — | — |
| P/S Ratio | 29.13 | 32.53 | 19.46 | 1.15 | 63.74 | — | — | — | — | — | — |
| P/B Ratio | 0.93 | 1.14 | 0.78 | 0.93 | 5.54 | — | — | — | — | — | — |
| P/FCF | — | — | — | 1.86 | — | — | — | — | — | — | — |
| P/OCF | — | — | — | 1.84 | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 20.17 | 10.42 | 0.71 | 56.69 | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | 1.13 | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | 1.16 | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | 1.15 | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Molecular Partners AG earns an operating margin of -1231.7%. Operating margins have compressed from 61.5% to -1231.7% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -34.0% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -855.8% | -855.8% | -579.8% | 73.2% | -497.2% | -500.1% | -113.4% | -50.7% | 11.0% | 36.8% | 96.0% |
| Operating Margin | -1231.7% | -1231.7% | -868.3% | 61.5% | -679.7% | -624.2% | -179.9% | -361.3% | -129.1% | -84.6% | -7.6% |
| Net Profit Margin | -1087.4% | -1087.4% | -880.7% | 62.2% | -683.7% | -671.7% | -178.0% | -357.7% | -127.0% | -80.8% | -0.5% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -34.0% | -34.0% | -30.1% | 68.8% | -59.5% | -77.8% | -49.8% | -35.5% | -20.1% | -12.9% | -0.1% |
| ROA | -30.3% | -30.3% | -26.9% | 54.2% | -35.4% | -42.9% | -27.9% | -24.7% | -15.5% | -9.2% | -0.1% |
| ROIC | -47.6% | -47.6% | -34.6% | 90.4% | -427.9% | — | — | — | — | — | — |
| ROCE | -36.9% | -36.9% | -28.5% | 62.9% | -49.6% | -56.6% | -37.7% | -30.1% | -17.3% | -10.8% | -1.2% |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $64M exceeds total debt of $2M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.02 | 0.02 | 0.06 | 0.07 | 0.05 | — | — | — | — |
| Debt / EBITDA | — | — | — | 0.04 | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.43 | -0.36 | -0.35 | -0.61 | -1.18 | -1.35 | -1.08 | -1.12 | -1.10 | -1.29 |
| Net Debt / EBITDA | — | — | — | -0.70 | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | -0.71 | — | — | — | — | — | — | -7.78 |
| Interest Coverage | -2448.68 | -2448.68 | -1247.10 | 179.92 | -115.73 | -215.23 | -364.32 | -366.76 | -131.19 | -218.94 | -14.40 |
Net cash position: cash ($64M) exceeds total debt ($2M)
Short-term solvency ratios and asset-utilisation metrics
Molecular Partners AG's current ratio of 14.31x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 14.77x to 14.31x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 14.31 | 14.31 | 13.35 | 14.77 | 3.50 | 3.08 | 3.49 | 4.16 | 10.08 | 11.52 | 8.20 |
| Quick Ratio | 14.31 | 14.31 | 13.35 | 14.77 | 3.50 | 3.09 | 3.51 | 4.22 | 10.75 | 11.52 | 8.20 |
| Cash Ratio | 13.86 | 13.86 | 12.96 | 14.44 | 2.83 | 3.01 | 3.32 | 2.68 | 9.98 | 11.43 | 8.14 |
| Asset Turnover | — | 0.03 | 0.04 | 0.72 | 0.05 | 0.05 | 0.19 | 0.07 | 0.14 | 0.13 | 0.13 |
| Inventory Turnover | 999999.00 | — | — | — | 999999.00 | — | — | — | — | — | 9.21 |
| Days Sales Outstanding | — | 21.00 | 90.50 | 3.27 | 1006.43 | 110.90 | 45.63 | 1819.36 | 21.03 | 13.37 | 16.85 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Molecular Partners AG does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | 54.0% | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | 53.8% | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.3% | 0.0% | — | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.3% | 0.0% | — | — | — | — | — | — |
| Shares Outstanding | — | $34M | $33M | $33M | $31M | $25M | $21M | $21M | $21M | $20M | $20M |
Compare MOLN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| MOLNYou | $188M | -2.4 | — | — | -855.8% | -1231.7% | -34.0% | -47.6% | — |
| REGN | $108B | 18.8 | 21.6 | 26.4 | 86.3% | 25.7% | 14.9% | 12.4% | 0.6 |
| CNTA | $4B | -13.0 | — | — | — | — | -73.9% | -91.8% | — |
| IMNM | $2B | -4.4 | — | — | 100.0% | -3382.4% | -194.6% | -700.3% | — |
| CLDX | $2B | -7.7 | — | — | 100.0% | -19160.0% | -40.6% | -35.2% | — |
| RXRX | $2B | -2.5 | — | — | 5.0% | -867.9% | -59.5% | -95.8% | — |
| NRIX | $2B | -5.2 | — | — | 77.5% | -340.2% | -49.6% | -54.0% | — |
| ROIV | $1B | -120.6 | — | — | 96.9% | -3453.3% | -3.0% | -50.4% | — |
| ABCL | $1B | -7.4 | — | — | — | -289.0% | -14.5% | -16.8% | — |
| ARVN | $975M | -10.4 | — | — | -151.8% | -45.1% | -16.2% | -23.1% | — |
| XNCR | $918M | -10.3 | — | — | — | — | -9.5% | — | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 12 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how MOLN stacks up against sector leader Regeneron Pharmaceuticals, Inc..
Start ComparisonMolecular Partners AG's current P/E ratio is -2.4x. The historical average is 1.9x.
Molecular Partners AG's return on equity (ROE) is -34.0%. The historical average is -19.9%.
Based on historical data, Molecular Partners AG is trading at a P/E of -2.4x. Compare with industry peers and growth rates for a complete picture.
Molecular Partners AG has -855.8% gross margin and -1231.7% operating margin.